New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
05:55 EDTDVA, DVA, WLP, WLP, MCK, MCK, CI, CI, BMY, BMY, MDT, MDT, COV, COV, BAYRY, BAYRY, EPOC, EPOC, AET, AET, AGN, AGN, HUM, HUM, BDX, BDXWharton School of Business to host a conference
19th Annual Wharton Healthcare Business Conference is being held in Philadelphia on February 14-15.
News For DVA;HUM;AGN;AET;EPOC;BAYRY;COV;MDT;BMY;CI;MCK;WLP;BDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
January 29, 2016
14:24 EDTCI, HUM, AETEarnings Watch: Aetna down 9% since last report
Aetna (AET) is scheduled to report fourth quarter earnings before the market open on Monday, February 1, with a conference call scheduled for 8:30 am ET. Aetna, a diversified health care benefits company in the United States, operates in three segments: Health Care, Group Insurance, and Large Case Pensions. EXPECTATIONS: Analysts are looking for earnings per share of $1.21 on revenue of $14.93B, according to First Call. The consensus range for EPS is $1.16-$1.32 on revenue of $14.44B-$15.36B. LAST QUARTER: Aetna reported third quarter EPS of $1.90 on revenue of $14.97B against analyst estimates of $1.77 and $14.95B, respectively. The company raised its fiscal 2015 EPS view to $7.45-$7.55 from "at least $7.40." Operating earnings were $668.6M for Q315 compared with $638.6M for Q314. The increase in operating earnings was primarily due to higher underwriting margins in Aetna's Health Care segment, partially offset by an increase in general and administrative expenses and lower underwriting margins in Aetna's Group Insurance segment. On January 11, Aetna said it see FY15 EPS at the high end of the $7.45-$7.55 range. Consensus for FY15 EPS is $7.54. STREET RESEARCH: On January 15, Wells Fargo said it expects health insurers' stock to do well this year, as the firm expects M&A deals made the last years to increase profits this year, and it thinks investors should be attracted to what it sees as the defensive names in the sector. Wells does not believe that any changes to or replacements of the ACA will be worse for the sector than the status quo. It identified Aetna and HCA Holdings (HCA) as its favorite names in the sector. On January 25, Leerink analyst Ana Gupte said she believed the recent selloff has provided a "strong" buying opportunity in the Managed Care space. Valuations are attractive on multiple metrics, Gupte told investors in a research note. Her top picks are UnitedHealth (UNH), Aetna, Humana (HUM) and Molina Healthcare (MOH). The analyst also favors Anthem (ANTM) and Cigna (CI). PRICE ACTION: Shares of Aetna are down approximately 9% since its last earnings report. The stock is up 2.6% to $101.42 in Friday afternoon trading ahead of Monday morning's report.
13:10 EDTAETAetna technical comments ahead of earnings
Subscribe for More Information
07:49 EDTBMYBristol-Myers, AbbVie receive 'positive' CHMP opinion for Empliciti
Subscribe for More Information
07:38 EDTAGNAllergan's Phase III rapastinel receives Breakthrough Therapy desgination by FDA
Subscribe for More Information
07:11 EDTAGNAllergan enters into global agreement with AstraZeneca for ATM-AVI
Allergan announced that it has entered into a global agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam. Together, the two companies will evaluate the combination to treat serious infections caused by metallo betalactamase MBL-producing Gram-negative pathogens, a difficult-to-treat sub-type of carbapenem-resistant Enterobacteriaceae, or CRE, for which there are currently very limited treatments, thus presenting a new treatment option for patients with MBL-producing pathogens. Under the terms of the agreement, Allergan will maintain commercialization rights in the U.S. and Canada and AstraZeneca will maintain commercialization rights in all other countries.
07:03 EDTAETAetna volatility elevated into Q4 and outlook
Aetna February weekly call option implied volatility is at 47, February and March is at 38; compared to its 52-week range of 18 to 44, suggesting large near term price movement into the expected release of Q4 results on February 1.
January 28, 2016
17:01 EDTAETAetna enters four-year reinsurance arrangement with Vitality Re VII
Aetna announced it has entered into a four-year reinsurance arrangement with Vitality Re VII. The arrangement allows Aetna to reduce its required capital and provides $200M of collateralized excess of loss reinsurance coverage on a portion of Aetna's group commercial health insurance business.
12:42 EDTBMYBristol-Myers says EU approves Daklinza for treatment of chronic hepatitis C
Bristol-Myers Squibb announced that the European Commission has approved Daklinza for the treatment of chronic hepatitis C in three new patient populations. The expanded label allows for the use of Daklinza in combination with sofosbuvir in HCV patients with decompensated cirrhosis, HIV-1 coinfection, and post-liver transplant recurrence of HCV in all 28 Member States of the European Union. Daklinza is already approved by the European Commission for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic HCV infection in adults, and the Daklinza + sofosbuvir regimen is the only approved 12-week, all-oral treatment for genotype 3 HCV patients without cirrhosis. The new indications are based on data from the ALLY-1 clinical trial and ALLY-2 clinical trial. The recommended treatment regimens and durations are as follows:
09:27 EDTBMYBristol-Myers reports Q4 US revenue $2.3B
Subscribe for More Information
09:27 EDTBMYBristol-Myers sees FY16 non-GAAP EPS $2.30-$2.40, consensus $2.29
Sees FY16 revenue up in mid-single digit range, consensus $17.4B. Sees FY16 gross margin as percentage of revenue ot be approximately 75%-76%. Sees FY16 marketing, sales and administrative expenses decreasing in mid-single digit range. Sees FY16 R&D expenses increasing in high-single digit range. Sees FY16 effective tax rate between 21%-22%.
09:25 EDTBMYBristol-Myers reports Q4 non-GAAP EPS 38c, consensus 28c
Reports Q4 revenue $4.29B, consensus $4.15B.
07:11 EDTBMYBristol-Myers: DMC concluded that CheckMate Phase 3 study met primary endpoint
07:00 EDTBMYBristol-Myers says CheckMate-141 Opdivo Phase 3 trial stopped early
Bristol-Myers Squibb announced that a randomized Phase 3 study evaluating Opdivo versus investigator's choice in patients with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck was stopped early because an assessment conducted by the independent Data Monitoring Committee concluded that the study met its primary endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm. The company looks forward to sharing these data with health authorities soon. "With the results of CheckMate -141, Opdivo moves closer to providing a potential treatment option for patients with head and neck cancer, a cancer with a high unmet need and limited treatment options," said Michael Giordano, M.D., senior vice president, head of Oncology Development, Bristol-Myers Squibb. "We look forward to continuing to advance the Opdivo clinical development program in hard-to-treat cancers, such as head and neck cancer." CheckMate -141 investigators have been informed of the decision to stop the trial early and Bristol-Myers Squibb is working to ensure that eligible patients be provided the opportunity to continue or start treatment with Opdivo as part of the company's commitment to providing patient access to Opdivo, and characterizing long-term survival. The company will complete a full evaluation of the final CheckMate -141 data, and work with investigators on the future presentation and publication of the results.
January 27, 2016
16:18 EDTMCKMcKesson sees FY17 adjusted EPS to grow 7%--12% excluding items
McKesson expects growth in adjusted EPS for FY17 to be between 3% and 8%, as reported, and between 7% and 12%, excluding 48c of gains on the disposition of two businesses and favorable discrete tax items in FY16.
16:17 EDTMCKMcKesson backs FY16 adjusted EPS $12.60-$12.90, consensus $12.77
Subscribe for More Information
16:16 EDTMCKMcKesson reports Q3 adjusted EPS $3.18, consensus $3.13
Reports Q3 revenue $47.9B, consensus $48.8B.
14:34 EDTBMYNotable companies reporting before tomorrow's open
Subscribe for More Information
14:34 EDTMCKNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Facebook (FB), consensus 68c... Qualcomm (QCOM), consensus 90c... Texas Instruments (TXN), consensus 69c... McKesson (MCK), consensus $3.13... PayPal (PYPL), consensus 35c... Las Vegas Sands (LVS), consensus 65c... eBay (EBAY), consensus 50c... Crown Castle (CCI), consensus $1.10... Vertex (VRTX), consensus 17c... Discover (DFS), consensus $1.30... SanDisk (SNDK), consensus 89c... ServiceNow (NOW), consensus 8c... Lam Research (LRCX), consensus $1.43... Citrix Systems (CTXS), consensus $1.19... Hologic (HOLX), consensus 42c... Juniper (JNPR), consensus 59c... Cavium (CAVM), consensus 28c... Cirrus Logic (CRUS), consensus 81c.
14:17 EDTBMYBristol-Myers technical comments before earnings news
Subscribe for More Information
13:55 EDTBMYBristol-Myers volatility elevated into Q4 and outlook
Bristol-Myers Black & Decker January weekly call option implied volatility is at 49, February is at 30; compared to its 52-week range of 18 to 43, suggesting large near term price movement into the expected release of Q4 results on January 28.
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use